Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences (NASDAQ: IDYA) will participate in several investor conferences throughout January 2022, showcasing its focus on precision medicine in oncology.

The events include the LifeSci Advisors Corporate Access Event on January 6, the J.P. Morgan 40th Annual Healthcare Conference on January 11, and the B. Riley Securities' 2022 Oncology Conference on January 27. CEO Yujiro Hata will present at all conferences, emphasizing IDEAYA's commitment to synthetic lethality and patient-targeted therapies.

IDEAYA Biosciences (Nasdaq:IDYA) announced a clinical update on its Phase 1/2 trial combining darovasertib and crizotinib for metastatic uveal melanoma (MUM) patients. With 22 heavily pre-treated patients enrolled, the interim results show a remarkable 100% Disease Control Rate and a 31% Overall Response Rate. The data suggests potential as a new treatment benchmark in this area with high unmet medical need. IDEAYA is also exploring the combination in other tumor types and expects further clinical data in 2022, aimed at regulatory feedback for potential registration.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, announced its participation in investor conferences in December 2021. Notably, they will host a fireside chat at the Evercore ISI HealthConX Conference on December 2, 2021, at 10:30 am ET, featuring CEO Yujiro Hata. A live audio webcast will be available on their website, with replays accessible for 30 days. IDEAYA focuses on discovering targeted therapeutics using synthetic lethality, enhancing treatment for specific patient populations through molecular diagnostics.

IDEAYA Biosciences (NASDAQ: IDYA) will provide a clinical data update on December 7, 2021, focusing on the ongoing Phase 1/2 trial of darovasertib and crizotinib for metastatic uveal melanoma. The company plans a pre-market press release and will host a conference call at 8:30 a.m. ET. Key discussion points include clinical efficacy data, potential registration-enabling trial designs, and target patient population analysis. This event aims to showcase clinical benchmarks and potential expansion into other cancer types.

IDEAYA Biosciences (Nasdaq: IDYA) reported a business update and Q3 2021 financial results. The company is advancing its Phase 1 MAT2A inhibitor, IDE397, with early clinical data showing tumor shrinkage in patients with MTAP deletion. IDEAYA also selected a lead candidate for its PARG program and is collaborating with GlaxoSmithKline (GSK) on multiple synthetic lethality programs. Financially, IDEAYA reported a net loss of $11.6 million, with cash reserves increasing to $385.8 million, sufficient to fund operations into 2025.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in key investor conferences in November 2021. Events include the Northland Capital Biotech Best Ideas Event on November 17, featuring CEO Yujiro Hata in a CEO Roundtable and a panel discussion on synthetic lethality. Additionally, Hata will present at 1:00 PM ET. The Jefferies London Healthcare Conference follows on November 18, with a fireside chat led by Maury Raycroft. Live audio webcasts will be available on IDEAYA's website, with replays accessible for 30 days.

IDEAYA Biosciences (NASDAQ: IDYA) has appointed Dr. Michael White as Chief Scientific Officer, effective November 1, 2021. Dr. White brings extensive experience from his role at Pfizer and a notable academic career at UT Southwestern. His leadership aims to strengthen IDEAYA's position in synthetic lethality and advance its pipeline, including the MAT2A inhibitor IDE397. He succeeds Dr. Michael Dillon, who contributed significantly since 2018. IDEAYA is committed to developing targeted therapeutics for precision medicine in oncology, focusing on biomarker-driven patient populations.

IDEAYA Biosciences (Nasdaq: IDYA) announced a business update and financial results for Q2 2021, reporting a net loss of $10.9 million. Cash reserves stood at $312.4 million, bolstered by a recent $86.5 million capital raise. The company highlighted clinical advancements in its synthetic lethality pipeline, including positive preliminary results for IDE397 in MTAP-deletion patients and promising data for darovasertib in metastatic uveal melanoma. IDEAYA aims for FDA guidance on darovasertib monotherapy in H2 2021 and anticipates two potential development candidates in Q4 2021.

IDEAYA Biosciences (NASDAQ: IDYA) will participate in a panel discussion titled "Synthetic Lethal (Weapon)" at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 11:30 am ET. The panel includes industry leaders like Michael Dillon, Chief Scientific Officer at IDEAYA, and Barbara Weber, CEO of Tango Therapeutics. A live audio webcast will be available on IDEAYA's website, with a replay accessible for 30 days post-event. IDEAYA is focused on synthetic lethality and targeted therapeutics, integrating biomarker identification with drug discovery.